Skip to main content

Omega Funds — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

79
Companies
$5.7B
Total invested
$96.1M
Avg. check
28
Industries
Biotechnology 19Health Care 15Medical 10Pharmaceutical 6Therapeutics 5Medical Device 5+22 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 79
Photys Therapeutics
September 2022

Photys Therapeutics’ proprietary bifunctional small molecules platform unlocks fine-tuned control of protein modifications.

Biotechnology · Cambridge$75.0M Series A
Thankful
September 2021

Thankful is a Developer of an automation software created to improve online customer service.

Artificial Intelligence (AI) · Los Angeles$12.0M Series A
Anjarium Biosciences
September 2021

Anjarium is focused on creating new class of non-viral gene therapies to deliver predictable ,inclusionary ways to tackle genetic diseases.

Biotechnology · Schlieren$60.4M Series A
GelSight
August 2022

GelSight provides extremely detailed and rapid surface measurements through the novel GelSight sensor technology.

Aerospace · WalthamConvertible Note
NeuroVision Imaging
August 2021

NeuroVision Imaging is a developer of digital imaging and diagnostic solutions for Alzheimer's disease.

Biotechnology · SacramentoGrant
etherna immunotherapies
August 2022

etherna develops mRNA and lipid nanoparticle solutions.

Biotechnology · Niel$38.9M Series B
XII Medical
August 2024

XII Medical provides minimally invasive technology for obstructive sleep apnea.

Health Care · Union City$45.0M Series B
CatalYm
July 2024

CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.

Biotechnology · Planegg$150.0M Series D
Ousia Pharma
May 2025

Ousia Pharma focuses on the design and development of pharmacotherapies to improve the health and lives of people living with obesity.

Biotechnology · CopenhagenSeed
Editas Medicine
May 2026

Editas Medicine is a clinical-stage genome editing company that develops genomic medicines for serious diseases.

Biotechnology · Cambridge$125.0M Post-IPO Equity
Sana Biotechnology
May 2026

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Biotechnology · Seattle$69.0M Post-IPO Equity
Antares Therapeutics
May 2025

Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.

Biopharma · Boston$177.0M Series A
Endeavor BioMedicines
April 2024

Endeavor BioMedicines develops new treatments targeting the underlying causes of pulmonary fibrosis.

Biotechnology · Solana Beach$132.5M Series C
Spruce Biosciences
April 2026

Spruce Biosciences is a biopharmaceutical company developing therapies for rare diseases that target the endocrine system.

Biopharma · South San Francisco$60.0M Post-IPO Equity
Trevi Therapeutics
April 2026

Trevi Therapeutics is a clinical-stage biopharmaceutical company that develops drugs for treating uremic pruritus.

Biotechnology · Sandy Hook$173.0M Post-IPO Equity
CDR-Life AG
April 2022

CDR-Life AG is a biotech company that develops innovative therapeutic antibody fragments with a focus on immuno-oncology.

Biotechnology · Schlieren$76.0M Series A
NRG Therapeutics
September 2025

NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function.

Biopharma · Cambridge$67.5M Series B
ARTBIO
July 2025

ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.

Biotechnology · Cambridge$132.0M Series B
Hydrocision
April 2025

HydroCision develops, manufactures, and markets fluid jet-based surgical tools for minimally invasive spine surgery requirements.

Health Care · North Billerica$2.5M Venture - Series Unknown
Callio Therapeutics
March 2025

Callio Therapeutics develops next-generation, multi-payload antibody-drug conjugates (ADCs).

Biotechnology · Seattle$187.0M Series A
Vanqua Bio
July 2024

Vanqua Bio is a biotechnology company that discovers and develops next-generation medicines for patients with neurodegenerative diseases.

Biotechnology · Chicago$45.0M Venture - Series Unknown
BBOT
May 2024

BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3K malignancies.

Biopharma · Palo Alto$200.0M Venture - Series Unknown
Eyebiotech
November 2023

Eyebiotech is an ophthalmology biotechnology company that specializes in therapies for eye diseases.

Biotechnology · New York$65.0M Series A
Spiro Medical
January 2026

Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment.

Biotechnology · Menlo Park$67.0M Series A

Where Omega Funds invests

Biotechnology19
Health Care15
Medical10
Pharmaceutical6
Therapeutics5
Medical Device5

About Omega Funds's portfolio

How many companies has Omega Funds invested in?

Omega Funds has invested in 79 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Omega Funds invest in?

Omega Funds's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 28 different industry categories.

What is Omega Funds's largest investment?

Among tracked funding rounds, BBOT received $200.0M in a Venture - Series Unknown round. Omega Funds's total known invested capital is $5.7B.

What is the average investment size for Omega Funds?

Omega Funds's average investment size is $96.1M across its portfolio of 79 companies.

What are Omega Funds's most recent investments?

Recent Omega Funds portfolio additions include Photys Therapeutics, Thankful, Anjarium Biosciences, GelSight, NeuroVision Imaging. These companies were founded in 2020 or later.

Reach the founders behind these 79 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →